GSK3B and acute kidney injury: The levels of p-S9-GSK3β or p-S675-β-catenin in cox2a-/- mutants and PKA inhibitor treatment groups were less than DMSO-treated control groups following AKI, respectively (Figure 7J–L, Q–S, X, Y).